about us

For more than a decade, we’ve forged new paths for gene therapies.

We have the largest and deepest ex-vivo gene therapy data set in the world—driving the field forward. We are currently developing gene therapies for severe genetic diseases.

bluebird bio recently announced the completion of its sale to funds managed by global investment firms and the appointment of a new management team, which is committed to rapidly scaling access to lifechanging gene therapies.